NYXOAH
Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions. Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
NYXOAH
Industry:
Health Care Medical Medical Device Neuroscience
Founded:
2009-01-01
Address:
Mont-saint-guibert, Brabant Wallon, Belgium
Country:
Belgium
Website Url:
http://www.nyxoah.com
Total Employee:
11+
Status:
Active
Contact:
(322)612-1755
Email Addresses:
[email protected]
Total Funding:
66 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Nginx Cloudflare JS YouTube Facebook Custom Audiences Apache 2.4 PostalAddress Schema Ubuntu
Similar Organizations
CeQur
CeQur develops and commercializes insulin delivery systems, giving people with type 2 diabetes freedom from multiple daily injections.
InTouch Health
InTouch Health is the leader in Acute Care Telemedicine solutions.
Minerva Surgical
Minerva Surgical is a medical device start-up company developing medical devices for women’s healthcare.
MIVI Neuroscience
MIVI Neuroscience focuses on developing and commercializing clinical solutions for neurointerventional procedures.
NinePoint Medical
NinePoint Medical is a transformational medical device company developing innovative, real-time, in vivo pathology devices.
Pulse Biosciences
Pulse Biosciences is a medical device company that engages in the research and development, and commercialization of CellFX system.
SceneRay
SceneRay is a medical device company dedicated to the design, Development, and distribution of neuromodulation devices.
Senseonics
Senseonics is a medical device startup company that focuses on the design, development, and commercialization of glucose monitoring systems.
Sinocelltech
Sinocelltech is a biotech company that develops and manufactures recombinant proteins, monoclonal antibodies, and vaccines.
Vascular Flow Technologies
Vascular Flow Tech focuses on research, development and commercialization of vascular devices based on new understanding of blood flow.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
ResMed
ResMed investment in Corporate Round - Nyxoah
Cochlear
Cochlear investment in Corporate Round - Nyxoah
Cochlear
Cochlear investment in Series C - Nyxoah
S.R.I.W.
S.R.I.W. investment in Series B - Nyxoah
Gilde Healthcare
Gilde Healthcare investment in Series B - Nyxoah
Viralety Ventures
Viralety Ventures investment in Series A - Nyxoah
Official Site Inspections
http://www.nyxoah.com Semrush global rank: 3.86 M Semrush visits lastest month: 3.37 K
- Host name: ec2-18-192-87-180.eu-central-1.compute.amazonaws.com
- IP address: 18.192.87.180
- Location: Frankfurt am Main Germany
- Latitude: 50.1188
- Longitude: 8.6843
- Timezone: Europe/Berlin
- Postal: 60313
More informations about "Nyxoah"
| Nyxoah
Nyxoah’s lead solution, Genio ®, uses hypoglossal nerve stimulation, an alternative to CPAP therapy, to treat obstructive sleep apnea, the world's most common sleep disordered breathing condition that is associated with …See details»
Nyxoah - Crunchbase Company Profile & Funding
Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep …See details»
Company Overview - investors.nyxoah.com
Mar 15, 2025 Nyxoah – DREAM & Inspire Medical – STAR Trials* Nyxoah – DREAM Design & Demographics Sample size n=115 Inclusion criteria AHI range: 15 -65 Requirement 60 …See details»
Nyxoah Company Overview
• Joined Nyxoah in July 2019 as Chief Operating and Commercial Officer, subsequently being appointed as CEO in November 2019. Loïc Moreau Chief Financial Officer • Experienced …See details»
Home | Nyxoah Investors
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah's flagship solution, Genio, uses hypoglossal nerve stimulation, an …See details»
Board of Directors - Nyxoah
Olivier Taelman is an experienced MedTech leader, joining Nyxoah in July 2019 as Chief Operating and Commercial Officer and subsequently being appointed as CEO in November …See details»
Nyxoah Company Profile - Office Locations, Competitors, Revenue …
Nyxoah has 5 employees at their 1 location and €4.35 m in annual revenue in FY 2023. See insights on Nyxoah including office locations, competitors, revenue, financials, executives, …See details»
Obstructive Sleep Apnea Treatment | Genio by Nyxoah
That's why Nyxoah created Genio. With Genio, You No Longer Have to Sleep With a Mask! Genio is a treatment for obstructive sleep apnea (OSA). It is indicated for patients who cannot tolerate or have failed continuous positive …See details»
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial …
• Full U.S. commercial organization, including sales, marketing, and market access teams, in place "2024 was a transformative year for Nyxoah. We reported best-in-class outcomes from …See details»
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial …
Mar 13, 2025 Nyxoah Reports Fourth Quarter and Financial Year ... Full U.S. commercial organization, including sales, marketing, and market access teams, in place " 2024 was a …See details»
The path to restful nights - Nyxoah Investors
Ciations ("CCA"). It was approved by the Board of Director of Nyxoah SA on [March 24], 2022. In this Annual Report, Nyxoah SA and its affiliates will be collectively referred to as “the …See details»
Nyxoah Aims to Replicate its European Success Stateside in 2024
Jan 18, 2024 Nyxoah SA, maker of the CE-marked Genio neurostimulator for the treatment of obstructive sleep apnea (OSA), outlined its strategic goals for 2024, focusing on pivotal study …See details»
Nyxoah files $200M mixed securities shelf | Markets Insider
1 day ago 18:23 EDT Nyxoah (NYXH) files $200M mixed securities shelf Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. …See details»
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial …
Mar 13, 2025 REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating ResultsFDA PMA Application Review Nearing …See details»
Product Security | Nyxoah
Nyxoah is committed to ensuring the safety and security of patients, caregivers, operators, and customers who use our products ... organization name) and preferably your PGP public key for …See details»
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial …
Mar 13, 2025 For the full year ending December 31, 2024, total cost of goods sold was € 1. 5 million, representing a gross profit of € 3. 0 million, or gross margin of 6 6 %. This compares to …See details»
Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare …
Mar 3, 2025 Nyxoah to Participate in the Oppenheimer 35 th Annual Healthcare MedTech & Services Conference. Mont-Saint-Guibert, Belgium – March 3, 2025, 10:30pm CET / 4:30pm …See details»
Nyxoah hiring Training & Education Manager (Sleep Implant
Mar 1, 2025 Nyxoah is seeking a Training & Education Manager to lead internal and ... Interfaces with the internal and external clients on behalf of the organization as a reliable …See details»
EQS-News: Nyxoah Reports Fourth Quarter and Financial Year …
Mar 13, 2025 Full U.S. commercial organization, including sales, marketing, and market access teams, in place "2024 was a transformative year for Nyxoah. We reported best-in-class …See details»
Nyxoah reports Q4 revenue EUR 1.3M - Markets Insider
Mar 13, 2025 “2024 was a transformative year for Nyxoah (NYXH). We reported best-in-class outcomes from our DREAM pivotal study, completed our PMA submission with the FDA for …See details»